Completed PHASE4 INTERVENTIONAL NCT00320736

Galantamine for Cognition in People With Schizophrenia

Effect of Nicotine Agonist Galantamine Added to High Potency Medications for Cognitive Function in Patients With Schizophrenia and Schizoaffective Disorder

Sponsor: Janssen Medical Affairs

Conditions Schizoaffective Disorder Schizophrenia

Interventions galantamine

Updated 5 times since 2017 Last updated: May 15, 2009 Started: Jan 31, 2004 Completion: May 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Schizoaffective Disorder and Schizophrenia and is currently completed. Janssen Medical Affairs leads this study, which shows 5 recorded versions since 2004 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jan 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen Medical Affairs
North Suffolk Mental Health Association

Data source: North Suffolk Mental Health Association

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States